Sunday, July 26, 2015

AstraZeneca chases biosimilar Avastin drug with Japanese group

LONDON (Reuters) - AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin.









No comments:

Post a Comment